Literature DB >> 10829333

Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later.

H V Curran1, C Morgan.   

Abstract

AIMS: Recreational use of the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, is increasing. The present study aimed to examine both the acute and residual effects of this drug on cognitive function, dissociation and schizotypal symptomatology in recreational users. DESIGN AND PARTICIPANTS: A parallel group design was used to compare 20 volunteers who reported having taken ketamine with 19 volunteers who reported no consumption of ketamine on the relevant night (day 0). All 39 participants were tested on day 0 and again 3 days later. On each test occasion a battery of tests was administered which tapped a wide range of memory functions, attention, dissociation, schizotypal symptomatology and mood.
FINDINGS: Groups were broadly matched for polydrug use apart from ketamine. Acute effects on day 0 replicated previous laboratory studies showing a broad spectrum of cognitive impairments following ketamine administration as well as marked dissociative effects and schizotypal symptomatology. Three days later, ketamine users had significantly higher scores than controls on both dissociation and schizotypal symptomatology. On some cognitive measures there were no group differences on day 3; however, on tests tapping semantic memory, the ketamine users showed persisting impairments compared with controls.
CONCLUSIONS: Ketamine appears to induce acute and severe impairments of working, episodic and semantic memory as well as psychotogenic and dissociative effects. Three days after drug ingestion, recreational users display semantic memory impairment and dissociative and schizotypal symptomatology which could reflect chronic or residual effects of taking the drug or pre-existing differences in ketamine users.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10829333     DOI: 10.1046/j.1360-0443.2000.9545759.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  46 in total

Review 1.  Depersonalisation disorder: a contemporary overview.

Authors:  Daphne Simeon
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 3.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

4.  First injection of ketamine among young injection drug users (IDUs) in three U.S. cities.

Authors:  Stephen E Lankenau; Bill Sanders; Jennifer Jackson Bloom; Dodi Hathazi; Erica Alarcon; Stephanie Tortu; Michael C Clatts
Journal:  Drug Alcohol Depend       Date:  2006-09-18       Impact factor: 4.492

5.  Effects of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine on visual signal detection performance in rats.

Authors:  Todd M Hillhouse; Christina R Merritt; Joseph H Porter
Journal:  Behav Pharmacol       Date:  2015-08       Impact factor: 2.293

6.  Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia.

Authors:  Jinsong Tang; Hannah L Morgan; Yanhui Liao; Philip R Corlett; Dong Wang; Hong Li; Yanqing Tang; Jindong Chen; Tieqiao Liu; Wei Hao; Paul C Fletcher; Xiaogang Chen
Journal:  Psychopharmacology (Berl)       Date:  2014-11-19       Impact factor: 4.530

Review 7.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

8.  Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.

Authors:  Kamilla W Miskowiak; Maj Vinberg; Ellen M Christensen; Jens D Bukh; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing
Journal:  Neuropsychopharmacology       Date:  2013-12-10       Impact factor: 7.853

9.  Ketamine impairs multiple cognitive domains in rhesus monkeys.

Authors:  Michael A Taffe; Sophia A Davis; Tannia Gutierrez; Lisa H Gold
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

10.  HIV Sexual Risk Behaviors among Ketamine and Non-Ketamine Using Criminal Offenders Prior to Prison Entry.

Authors:  Carrie Oser; Jennifer Havens; Michele Staton-Tindall; Conrad Wong; Carl Leukefeld; Michael Prendergast
Journal:  Addict Res Theory       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.